Repros Low-Testosterone Therapy NDA May Be Delayed Until 4Q 2014

The company is preparing two head-to-head studies against approved testosterone replacement therapies to try to demonstrate Androxal’s superiority, even as apparent data fraud at a study site may alter the final analysis of a pivotal Phase III study.